Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Saved in:
| Title: | Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP). |
|---|---|
| Authors: | Turner N; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom., Saura C; Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Aftimos P; Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium., van den Tweel E; Byondis B.V., Nijmegen, the Netherlands., Oesterholt M; Byondis B.V., Nijmegen, the Netherlands., Koper N; Byondis B.V., Nijmegen, the Netherlands., Colleoni M; Division of Medical Senology, European Institute of Oncology, Milan, Italy., Kaczmarek E; Medical Oncology Department, Centre Oscar Lambret, Lille, France., Punie K; Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium., Song X; Medical Oncology, The Ottawa Hospital Cancer Center, Ottawa, ON, Canada., Armstrong A; Medical Oncology, The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom., Bianchi G; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Stradella A; Department of Medical Oncology, Institut Català d'Oncologia-L'Hospitalet IDIBELL, Barcelona, Spain., Ladoire S; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France., Lim JSJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Quenel-Tueux N; Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France., Tan TJ; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Escrivá-de-Romaní S; Medical Oncology Department, Vall d'Hebron University Hospital, and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., O'Shaughnessy J; Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX. |
| Corporate Authors: | TULIP Trial Investigators |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Feb 10; Vol. 43 (5), pp. 513-523. Date of Electronic Publication: 2024 Oct 23. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
